News
-
-
PRESS RELEASE
Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024
Catheter Precision, Inc. reports 15% quarter-over-quarter growth with initial sales of LockeT recorded, generating total revenue of $94,840 for Q2 ending June 30, 2024 -
-
-
-
PRESS RELEASE
Catheter Precision, Inc. Announces Receipt of LockeT Purchase Order for Eisenhower Medical Center, a Third California Hospital
Catheter Precision, Inc. announces new purchase order for LockeT, a suture retention device. The US-based medical device company focuses on electrophysiology products -
-
PRESS RELEASE
Catheter Precision, Inc. (NYSE: VTAK) Announces Initial Orders from Ronald Reagan UCLA Medical Center and Rady Children’s Hospital in San Diego for LockeT
Catheter Precision, Inc. announces additional product evaluations for LockeT, a suture retention device for hemostasis. The company expands US sales team for national launch -
-